MIC-value S / R (μg/ml) > Ampicillin, AMP E. coli EURL EC 11.8 Azithromycin, AZT Cefotaxime, FOT Ceftazidime, TAZ Chloramphenicol, CHL Ciprofloxacin CIP Colistin, COL Gentamicin, GEN Meropenem, MERO Nalidixic acid, NAL Sulfamethoxazole, SMX Tetracycline, TET Tigecycline, TGC Trimethoprim, TMP All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. See further description of confirmatory tests in the protocol section E. coli’. ‘3.1.1 Strain Antimicrobial Results and interpretation MIC-value S / R (μg/ml) > E. coli Cefepime, FEP EURL EC 11.8 Cefotaxime, FOT Cefotaxime + clavulanic acid (F/C) Cefoxitin, FOX Ceftazidime, TAZ Ceftazidime+ clavulanic acid (T/C) Ertapenem, ETP Imipenem, IMI Meropenem, MERO Temocillin, TRM Interpretation of PANEL 2 results: Presumptive ESBL Presumptive AmpC Other phenotype Presumptive ESBL+ AmpC Presumptive carbapenemase Susceptible
> MIC-value (μg/ml) S / R E. coli EURL EC 11.8 Ampicillin, AMP Azithromycin, AZT Cefotaxime, FOT Ceftazidime, TAZ Chloramphenicol, CHL Ciprofloxacin CIP Colistin, COL Gentamicin, GEN Meropenem, MERO Nalidixic acid, NAL Sulfamethoxazole, SMX Tetracycline, TET Tigecycline, TGC Trimethoprim, TMP All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) should be included for testing in the second panel confirmatory tests for ESBL or carbapenemase production. See further description of confirmatory tests in the protocol section ‘3.1.1 E. coli’. Strain Antimicrobial Results and interpretation > MIC-value (μg/ml) S / R E. coli EURL EC 11.8 Cefepime, FEP Cefotaxime, FOT Cefotaxime + clavulanic acid (F/C) Cefoxitin, FOX Ceftazidime, TAZ Ceftazidime+ clavulanic acid (T/C) Ertapenem, ETP Imipenem, IMI Meropenem, MERO Temocillin, TRM Interpretation of PANEL 2 results: Presumptive ESBL Presumptive ESBL+ AmpC Presumptive AmpC Presumptive carbapenemase Other phenotype Susceptible
357_test-forms-eurl-ar-eqas-ec-ent-st-2017.docx